Company news
Zealand Pharma A/s (OMXCOP:ZEAL) news
Every Zealand Pharma A/s press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Zealand Pharma - Transactions related to share buy-back program (week 36, 2026)
September 7, 2026
Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)
August 31, 2026
Zealand Pharma – Notification of holding of treasury shares
August 24, 2026
Zealand Pharma - Transactions related to share buy-back program (week 34, 2026)
August 24, 2026
Zealand Pharma - Transactions related to share buy-back program (week 33, 2026)
August 17, 2026
Zealand Pharma - Transactions related to share buy-back program (week 32, 2026)
August 10, 2026
Zealand Pharma - Transactions related to share buy-back program (week 31, 2026)
August 3, 2026
Zealand Pharma: Transactions related to share buy-back program (week 29, 2026)
July 20, 2026
Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)
July 13, 2026
Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)
July 6, 2026
Total number of shares and voting rights in Zealand Pharma as of June 30, 2026
June 30, 2026
Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.
June 30, 2026
Zealand Pharma - Transactions related to share buy-back program (week 26, 2026)
June 29, 2026
Zealand Pharma - Transactions related to share buy-back program (week 25, 2026)
June 22, 2026
Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)
June 15, 2026
Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)
June 8, 2026
Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral an...
June 7, 2026
Zealand Pharma to participate in the Goldman Sachs Global Healthcare Conference
June 2, 2026
Zealand Pharma - Transactions related to share buy-back program (week 22, 2026)
June 1, 2026
Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions
May 27, 2026
Zealand Pharma - Transactions related to share buy-back program (week 21, 2026)
May 26, 2026
Resolutions from Zealand Pharma's Extraordinary General Meeting 2026
May 26, 2026
Zealand Pharma - Transactions related to share buy-back program (weeks 19-20, 2026)
May 14, 2026
Zealand Pharma A/S : Q1 Financial Results / Interim Report First Quarter 2026
May 8, 2026
Zealand Pharma A/S : Interim Report for Q1 2026
May 8, 2026
Zealand Pharma Announces Financial Results for the First Three Months of 2026
May 7, 2026
Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program
May 7, 2026
Zealand Pharma convenes Extraordinary General Meeting on May 26, 2026
May 1, 2026
Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results
April 30, 2026
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
April 29, 2026
Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% d...
April 28, 2026
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely a...
April 22, 2026
Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026
April 19, 2026
Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations
April 14, 2026
Total number of shares and voting rights in Zealand Pharma as of March 31, 2026
March 31, 2026
Resolutions from Zealand Pharma's Annual General Meeting 2026
March 26, 2026
Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Cr...
March 24, 2026
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
March 19, 2026
Zealand Pharma to participate in upcoming investor conferences in March 2026
March 9, 2026
Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management exp...
March 5, 2026
Zealand Pharma convenes its Annual General Meeting 2026
February 19, 2026
Zealand Pharma Announces Financial Results for the Full Year 2025
February 19, 2026
Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830
February 18, 2026
Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results
February 12, 2026
Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030...
January 9, 2026
Zealand Pharma to present at the J.P. Morgan Healthcare Conference
January 5, 2026
Total number of shares and voting rights in Zealand Pharma as of December 31, 2025
December 31, 2025
Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health
December 11, 2025
Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for m...
December 11, 2025
REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025
December 1, 2025